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The acute effects of ACE inhibition on neurohormonal activation are complex.
Sympathetic tone decreases as a direct result of angiotensin II reduction;
however, an increase in bradykinin may stimulate sympathetic tone. Conse-
quently, divergent coronary and systemic hemodynamic effects may ensue.
As these acute ACE inhibitor effects are incompletely identified in humans,
49 pts with significant (>70%) CAD received enalaprilat. perindoprilat or cap-
topril intravenously, which resulted in immediate 1:0:5') 73% ACE inhibition
and a 52% reduction in arterial angiotensin II. Twenty-two patients received
placebo. During a 15-minute study protocol. placebo induced no changes. In
the treated group, arterial norepinephrine (NE) increased at 5 and 15 minutes
by 11 % and 12%, respectively, and arterial epinephrine (E) by 11 % and 14%,
respectively. Heart rate did not change, but contractility (VMAX) increased by
13% and 4%, respectively. Mean arterial pressure (MAP) decreased by 2%
and 5% and systemic vascular resistance (SVR) decreased by 4% and 7%,
respectively. Despite the reduction in coronary perfusion pressure, coronary
blood flow (CBFj increased by 8% at 5 minutes, while coronary vascular re-
sistance ICVR) decreased by 10% and 11 %, respectively, at 5 and 15 min-
utes. ArteriaI6-keto-F2a, the prostacyclin metabolite, was 52% higher com-
pared to placebo, but increased late, at 15 minutes. Other prostaglandins
and cardiac neurohormonal balances remained unaltered. Thus, in contrast
to the well-known modulation of sympathetic activity by chronic converting
enzyme inhibition, acute ACE inhibition results in an immediate increase in
cirCUlating catecholamines and improves myocardial contractility and coro-
nary flow. The effect on sympathetic tone and contractility cannot be ex-
plained by changes in circulating angiotensin II and prostaglandins or cardiac
renin-angiotensin, which suggests a bradykinin-related effect.
Ad F.M. van den Heuvel, Martin van der Ent Willem J. Remme Sticares Foundation,
Rotterdam, The Netherlands
pressor vasoactivity correctly predicted the presence of coronary disease in
76% of the subjects using a predetermined criterion. Mean flow-mediated di-
ameterincreased 9.11 ± 6.01 % and 6.58 ± 7.50% in the normal and coronary
disease subjects, respectively (P = NS), Responses to sublingual nitroglyc-
erin were the same in the two groups. Using multiple stepwise regression
analysis, cold-pressor vasoactivity was found to be dependent upon smoking
status (p = 0.0002) and the presence of coronary disease (p = 0.04). In the
32 non-smokers undergoing assessment, the presence of coronary disease
was the only significant determinant of cold pressor vasoactivity (p ~ 0.02).
Flow-mediated vasoactivity was found to be dependent on smoking status
(p = 0.005) and baseline brachial artery diameter (p = 0.02), Flow-mediated
vasoactivity correlated with total cholesterol by univariate but not multivari-
ate analysis. The associations of brachial artery vasoactivity with cardiac risk
factors and coronary disease appear to be stimulus dependent. Cold pressor
vasoactivity correlates more closely with the presence of coronary disease
than does flow-mediated vasoactiVity, These findings suggest that abnormal
cold pressor vasoactivity is a generalized vascular marker for atherosclero-
sis, but that flow-mediated vasoactivity correlates with the presence of risk
factors.
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Brachial Artery Vasoactivity: Cold Pressor but not
Flow-Mediated Responses Correlate with the
Presence of Coronary Artery Disease
Robert A. Vogel, Mary C. Corretti, Gary D. Plotnick. University of Mary/and School of
Medicine, Baltimore, MD
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Cigarette Smoking Inhibits Basal but not Stimulated
Release of Nitric Oxide from the Forearm Vasculature
Gary E. McVeigh. Lisa LeMay. Dennis J. Morgan. Jay N. Cohn. University of
Minnesota, Minneapolis. MN
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Risk Factor Modification Improves Flow-Mediated
Brachial Artery Vasoactivity but not Cold Pressor
Vasoactivity in Men with Coronary Artery Disease
Mary C. Corretti, Gary D. Plotnick, Michael Miller, Robert A. Vogel. University of
Maryland Hospital, 8a/~'more, MD
To evaluate the effects of cigarette smoking on endothelial function, we ex-
amined forearm vascular responses to the intra-brachial infusion of metha-
choline (MCj, NG-monomethyl-L-arginine (L-NMMA) and sodium nitroprus-
side (SN) in 36 smokers (S) and 11 non-smoking (NS) control subjects. Val-
ues are presented as means ± standard deviation. The mean age of S (42
± 7 years) was similar to NS (43 ± 11 years). Blood glucose, total and HDL-
cholesterol and serum fibrinogen concentrations were not different between
groups. S had elevated carboxyhemoglobin levels compared with NS (5.1 ±
2.5% vs, 1.1 ± 0.3%, P < 0.001). The incremental infusions of MC increased
forearm blood flow (FBF) (mill 00 ml/min) from 3.6 ± 1.2 to 12.7 ± 8.9 in S
and from 3.1 ± 0.8 to 14.7 ± 7.5 in NS (p = NS). SN increased FBF (mill 00
mllmin) from 3.7 ± 1.4 to 9.0 ± 4.7 in S and from 2.8 ± 0.3 to 8.4 ± 47 in NS
(p = NS). L-NMMA reduced FBF (m11100 mllmin) more (p = 0.03) in NS (3.9
± 0.5 to 2.2 ± 0.7) than in S (4.1 ± 1.5 to 3.3 ± 1.2) but did not attenuate the
dose response curves to MC infusion in either group.
Conclusion: Chronic cigarette smoking appears to impair basal but not
stimulated release of endothelium-derived nitric oxide from the forearm vas-
culature.
'p <0.01
FM vasoactivity normalized with risk factor modification and was similar to
our controls 11.5 ± 7.0%. CP response remained abnormal despite chronic
RFM. This suggests that FM vasoactivity is dependent on risk factor status,
but CP vasoactivity may be dependent on the presence of CAD.
Coronary risk factors are associated with impaired endothelium-mediated va-
soactivity in the peripheral and coronary circulation. To determine the effect
of risk factor modification (RFM) on brachial artery vasoactivity, we studied 23
men with coronary artery disease (CAD). Using 7.5 MHz ultrasound, brachial
artery diameter changes (%tl. Diam) in response to flow mediated (FM) and
cold pressor {CP} stimuli were measured in 13 men 1 week after the initial
presentation of ischemic heart disease and in another 10 men 1 year after
aggressive risk factor modification, (smoking cessation, lipid lowering).
Chronically managed patients had significantly lower total cholesterol and
smoking frequency.
Flow-mediated brachial artery vasoactivity is abnormal in patients with coro-
nary artery disease and cardiac risk factors. Cold pressor coronary artery va-
soactivity is abnormal in patients with coronary disease, but brachial artery
responses have not been studied. The purpose of this study was to assess
whether cold pressor and flow-mediated brachial artery vasoactivity corre-
late independently with the presence of coronary artery disease. We stud-
ied 50 men (27 clinically normal, 23 angiographically proven coronary artery
disease) ranging from 23 to 59 years old. Using 7.5 MHz ultrasound, we
measured brachial artery diameter and Doppler flow velocity at baseline,
during contralateral ice water hand immersion (cold pressor), following five
minutes of ipsilateral blood pressure cuff occlusion (flow-mediated) and fol-
lowing nitroglycerin administration. During cold pressor stimulation, mean
brachial artery diameter increased 0.36 ± 2.93% in the normal subjects but
decreased 2,38 ± 3.32% in the coronary disease subjects (p = 0.006). Cold
1787-21 Addition of ACE Inhibitors to Beta Blockers or
Calcium Channel Blockers Improves Mortality in
Patients with CAD
Rahul Chaturvedi, David Zurakowski, Saumya Sharma, GVR.K. Sharma. Dept. of
Medicine, Brockton-WestRoxburyVA.M.C., Harvard Medical School, 80ston, MA
Patients (n = 3676) with the diagnosis (Dx) of CAD discharged from our insti-
tution from 1/88 and 1/93 were followed for a mean duration of 33.3 months.
Using multiple logistic regression, with all cause mortality as the end point,
combinations of therapy (Rx) with either ACE inhibitors (A) or beta blockers
(B) or calcium channel blockers IC) were compared to Rx with C alone (n =
378). Age and the Dx of CHF, MI, COPD, DM, PVD, hypercholesterolemia,
CABG and PTCA were entered into the model. Results:
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Rx odds ratio p value 95% C.I.
A+B 197 0.51 <0.01 033-0.79
A+B+C 558 0.58 <0.01 0.42-0.81
B 429 0.66 003 0.46-095
B+C 794 0.7 002 052-0.95
A+C 291 0.96 081 0.67-137
A 197 1.16 0.47 0.78-1.72
None 832 1.88 <0.001 1.42-250
MI
All
WMI not available
WMI>1.2
WMI:51.2
WM I :5 1.2 Randomised
WMI < 1.2 Excluded
n
7001
475
3920
2606
1747
859
1 year mortality
23± 1%
50±4%
12± 1%
34± 2%
24± 1%
54±3%
Rx with A in combination with 8 significantly improves mortality when com-
pared to Rx with C even after controlling for CHF Significant differences in
the prevalence of CH F in various Rx groups (53% in A and 5% in Band 11 %
in C) and inability to adequately control for the severity of CHF may explain
the observed effect of Rx with A alone. Conclusions: Combination Rx with A
and 8 is preferable to Rx with Calone. It appears that mortality benefit ofACE
Inhibition in patients with CAD is not limited to patients who have CHF
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1787-31 Efficacy and Safety of Early Administration of
Intravenous Enalaprllat in Congestive Heart Failure
Patients with Acute Pulmonary Edema
Djillali Annane, Eric Bellissant, Eric Pussard, Roland Asmar, Florence Lacombe,
Olivier Madonna, Michel Safar, Jean-Fran~ois Giudicelli, Philippe Gajdos.
Reanimation Medicafe, H6pital R. Poincare, Garches, France
The systemic (Swan-Ganz cathet r, brachial sphygmomanometer) and EIl-
gional (20 pulsed doppler, paraaminohippurate and indocyanine green clear-
ances) hemodynamic and blood gases effects of a single intravenous 2-h-
infusion of 1 mg enalaprilat (E) were investigated within the 12 h following
an acute pulmonary edema episode and compared to those of a placebo (P)
in a randomized double-blind study performed in 20 CHF 11I1-IV NYHA) pa-
tients. The effects were investigated before and 2, 4 and 8 h after the onset
of treatment infusion. At peak effect, and as compared to P, E significantly
decreased pulmonary wedge pressure (-37 vs -10%, P = 0.001), diastolic
and mean systemic (-21 vs -4%, P = 0.009, -18 vs -6%, p ~ 0.026) and
pulmonary (-21 vs -8%, p = 0.040, -18 vs -9%, p = 0.046) arterial pres-
sures, brachial and renal resistances (-44 vs -14%, P = 0.017, -22 vs -2%,
P = 0.014) and significantly increased brachial and renal blood flows (+ 77
vs +8%, P = 0.036, + 12 vs 0%, p = 0.043) arterial oxygen tension (+ 2 vs
-8%, P = 0.041) and saturation (+ 1vs -2%, P = 0.045) and finally tended to
improve intra-pulmonary shunt (-18 vs -16%, P = 0.080). Simultaneously,
E did not affect heart rate, cardiac output, systolic systemic and pulmonary
arterial pressures, and carotid and hepato-splanchnic hemodynamics. Time
courses of plasma electrolytes, creatinine and nitrogen clearances were not
significantly different between E and P. We conclude that in this study early
administration of intravenous enalaprilat was effective and well tolerated in
CHF patients with acute pulmonary edema.
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1787-41 The Paradox of Low Risk Among High Risk Patients
in Controlled Trials - Experience In the TRAndolapril
Cardiac Evaluation Trial
Lars K"ber, Christian Torp-Pedersen, TRACE study group. Gentofte University
Hospital, Copenhagen, Denmark
Mortality in epidemiological studies is almost always larger than in appar-
ently similar populations selected for a clinical trial. To study this problem,
patient inclusion was tracked very carefully in the Trandolapril Cardiac eval-
uation (TRACE) trial.
The TRACE Register includes 7001 consecutive enzyme confirmed MIs in
6676 patients screened for entry into the trial. Medical history and compli-
cations of MI were obtained for all patients. Left ventricular systolic function
was determined by echocardiography in a core laboratory as wall motion
index (WMI) within 6 days of the infarction. Patients with WMI S 12 were
eligible for the study (corresponding to an ejection fraction below 35%) un-
less an exclusion criterion was present. Patients excluded were those not
tolerating or requiring an ACE inhibitor, those dying during screening phase
and those unwillinglunable to participate. Survival data were available for all
except 5 patients after 2-3 years.
The table shows number of MI and 1 year mortality in all patients, and
patients subgroubed by left ventricular systolic function. Also shown is pa-
tients with left ventricular dysfunction subgroubed by whether they were
randomised.
Conclusion: Even though the target population of high risk patients with
reduced left ventricular function was successfully identified, the final study
population had a 1 year mortality similar to unselected patients. This was
caused by exclusion of patients at extreme risk.
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1787-51 Systemic Effect of Ramipril on Endothelin, but not on
Eicosanoid Levels in Patients with Coronary Artery
Disease
Bernhard R. Winkelmann, Gerian Granefeld, Karen Nelson, Matti Verho,
Norbert Bender, Roland Kirsten, Wolfgang Schulz, Martin Kaltenbach. Johann
Wolfgang Goethe-University and Cardiovascular Research Hoechst and Cassella AG,
Frankfurt. Germany
Study aim: Neurohumoral effects of ramipril (R) alone or in combination with
isosorbide dinitrate (ISDN) compared to ISDN or placebo.
Study design: Placebo-controlled double-blind parallel group trial.
Methods: 32 patients with coronary artery disease (CAD) received placebo,
R 5 mg, ISDN 20 mg slow release b.Ld. or R + ISDN for one week. A 24 hour
kinetic profile of ramipril and its metabolite, of ace activity (ACE-A) and of re-
lated hormones (renin and aldosterone), of endothelin and of prostaglandins
(pG), thromboxane B2 {TXB2l. PGF2a, 6-keto PGF1 a, the stable metabolite of
prostacyclin (PGI2-M) was studied after the first dose. Measurements were
repeated after 8 days of treatment before and 3 hours after the morning
dose.
Results: Hormone measurements are presented as means of percent dif-
ference of patients treated with R (n = 16) vs. those without ace-inhibitor (n
= 16).
Time (hrs) a 1 2 3 4 6 8 24 Q-B 3-8
Ramipril(mgm a 8 5 4 3 2 1 0.4 1 7
Ramiprilat(mg/l) a 6 11 10 8 7 5 1 2 14
ACE-A(%) -6 -78 -95 -98 -98 -97 -96 -80 -82 -98
Aldosteron (%) 9 -5 -31 -34 -21 -27 -23 -34
Renin (%) -9 -7 7 19 13 17 53 32
Endothelin (%) -17 -13 -25 -19 -16 -15 -4 a
TXB2 (%) 4 10 4 5 5 a 12 -3
PGF2a 1%) 10 17 0 0 8 2 2 -9
PGI2-M(%) 7 a -3 8 -5 9 -1 -7 13
- = not done; significant differences are printed in italics (two-tailed t-test)
A single oral dose of 5 mg R reduced ACE activity (p < 0.001), decreased
aldosterone and increased renin (p < 0.1). R did not influence plasma levels
of the vasoconstricting (TXB2, PGF2al or vasodilating {pGI2-MI eicosanoid
mediators, but decreased endothelin (p < 0.1).
Conclusion: R, in a dose that results in significant systemic inhibition of the
renin angiotensin aldosteron system, does not induce measurable changes
of circulating eicosanoid concentrations, but seems to diminish systemic
release of endothelin.
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Hypotension Induced by Captopril in Patients with
Primary Autonomic Failure Occurs Independently of
Plasma Renin Levels and Sympathetic Nervous
Activity
J.S. Kooner 1, R. Baliga 1, WS. Peart, c.J. Mathias. 1Royal Postgraduate Medical
School, Hammersmith Hospital, London, UK.; St Mary's Hospital Medical School,
London, UK.
We have investigated the haemodynamic and hormonal responses to an-
giotensin converting enzyme inhibition in 12 patients with primary autonomic
failure (AF, 5 pure autonomic failure, 7 multiple system atrophy) and 7 nor-
mal subjects. Measurements of blood pressure (BP). heart rate (HR). stroke
distance (SO) and cardiac index (CI, continuous wave Doppler, forearm blood
flow (FBF, strain gauge plethysmography) and digital skin blood flow (DSBF,
laser Doppler flowmetry) were made non-invasively. Plasma renin activity
(PRA) and noradrenaline (NGRAD) were measured before and at 30 min in-
tervals after captopril (50 mg, oral).
Basal supine BP was higher in AF compared to normals (p < 0.05). After
captopril, mean BP fell in AF (117 ± 6 to 103 ± 5 mmHg, p < 0.05). but not in
normals (99 ± 4 to 97 ± 5 mmHg, ns). HR was unchanged after captopril in
both groups. The depressor response in AF was accompanied by a fall in SO
